---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-24-000003"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:58:03.174242+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DexCom reports preliminary Q4 revenue ≥$1.03B (+26% YoY); FY2024 guidance $4.15-4.35B

## Summary
- Preliminary Q4 2023 revenue at least $1.030B, up 26% YoY; FY2023 revenue ~$3.62B (+24%).
- FY2024 revenue guidance $4.15-4.35B, representing organic growth of 16-21%.
- Non-GAAP gross profit margin guidance 63-64% for FY2024; operating margin ~20%.
- Submitted Stelo glucose sensor for type 2 non-insulin users to FDA; expected U.S. launch summer 2024.
- U.S. Q4 revenue ~$765M (+26% YoY); international ~$265M (+27% YoY).

## SEC filing metadata
- accession: 0001093557-24-000003
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/dxcm-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-24-000003
- JSON: https://secwatch.observer/filing/0001093557-24-000003.json
- Plain text: https://secwatch.observer/filing/0001093557-24-000003.txt

## Key facts
- Earnings Releases
  DEXCOM INC reported the fourth quarter ended December 31, 2023 results: revenue $1.030 billion.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $1.030 billion
  - Result: preliminary results
  source text: preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 is expected to be at least $1.030 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm
- Earnings Releases
  DEXCOM INC reported fiscal year 2024 results: revenue $4.15 billion to $4.35 billion. Guidance initiated.
  - Period: fiscal year 2024
  - Revenue: $4.15 billion to $4.35 billion
  - Guidance: initiated
  - Result: guidance update
  source text: For 2024, Dexcom currently anticipates total revenue of approximately $4.15 billion to $4.35 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm
- Earnings Releases
  DEXCOM INC reported fiscal year 2023 results: revenue $3.62 billion.
  - Period: fiscal year 2023
  - Revenue: $3.62 billion
  - Result: preliminary results
  source text: For fiscal year 2023, total preliminary, unaudited revenue is expected to be approximately $3.62 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000003/0001093557-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.